Payer Denial Tactics — How to Confront a $20 Billion Problem

The American Hospital Association's report documenting that hospitals spend nearly $20 billion annually appealing denied claims — with more than half of those denials ultimately overturned — exposes a healthcare financing dynamic that physician practices experience at a smaller but equally consequential scale. Twenty billion dollars spent annually on an activity whose primary purpose is to recover revenue that should have been paid on initial submission. This is not a cost of healthcare delivery. It is a cost of healthcare denial, and it flows directly from payer practices that the AHA characterizes as systematic denial tactics.

The $20 Billion Arithmetic

The $20 billion figure represents the aggregate cost to hospitals and health systems of managing the denial and appeal cycle. It includes staff salaries for denial management teams, technology costs for tracking and processing appeals, legal and compliance expenses, and the opportunity cost of administrative resources diverted from other functions. For hospitals, these costs are partially absorbed into operating margins and partially passed through to patients and purchasers as higher prices.

For physician practices, the absolute numbers are smaller, but the proportional burden can be even greater. A hospital system can spread denial management costs across a large administrative infrastructure. A five-physician practice absorbs the same per-denial cost with a fraction of the administrative capacity. The MGMA estimates that denial management can consume 5 to 10 percent of a practice's total administrative budget — a figure that has grown steadily as denial rates have increased.

The Overturn Rate Paradox

The AHA's finding that more than half of denials are overturned on appeal creates a paradox that every practice leader should consider. If the majority of denials are reversed when challenged, what does that say about the quality of the initial denial decision? Two interpretations are possible:

• Charitable interpretation: Initial claim review is necessarily limited, and the appeal process provides the additional information needed for an accurate determination
• Critical interpretation: Payers systematically deny claims at rates they know to be excessive, relying on the low appeal rate to retain payment on the majority of inappropriate denials

The evidence increasingly supports the critical interpretation. The OIG has documented that MA plans deny covered services at measurable rates. The KFF has shown that appeal rates are vanishingly low. When denials are cheap to issue and expensive to contest, the economic incentive favors over-denial. The $20 billion cost is borne by providers, not by the payers issuing the denials.

Payer Denial Tactics Identified by the AHA

The AHA report identifies specific tactics that drive the denial volume:

• Expanding prior authorization requirements to more services and more clinical scenarios
• Applying clinical criteria that are more restrictive than published coverage policies
• Requiring documentation that exceeds what is clinically standard for the service provided
• Using automated review systems that deny based on pattern matching rather than clinical evaluation
• Implementing complex appeal processes with short timelines that deter or prevent challenges

Each of these tactics increases the probability of initial denial while raising the cost and complexity of appeal. The cumulative effect is the $20 billion annual expenditure the AHA documents.

The Practice-Level Response

For physician practices, the $20 billion figure is a systemic problem. The practice-level response is operational: building denial management processes that make appealing worthwhile denials efficient enough to be economically viable. The data consistently shows that appeals succeed more often than not. The challenge is doing it at a cost that makes the recovered revenue meaningful. Practices that build systematic, evidence-based appeal workflows convert the payer denial tactic from a revenue loss into a recoverable cost. Those that do not are paying their share of the $20 billion without contesting it.